BRAVE Strategy - Breast Cancer Risk Assessment -achieVing Equity
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Breast Cancer
- Sponsor
- Vanderbilt University Medical Center
- Enrollment
- 1071
- Locations
- 1
- Primary Endpoint
- Number of Eligible Women Who Received Breast Cancer Risk Assessment
- Status
- Completed
- Last Updated
- 8 months ago
Overview
Brief Summary
The central goal of this study is to test strategies to implement evidence-based breast cancer risk assessment in healthcare clinics in Tennessee. The BRAVE Strategy (Breast cancer Risk Assessment - achieVing Equity) study aims to assess the feasibility, reach, acceptability, and appropriateness of select customized strategies to increase uptake of breast cancer risk assessment. The investigators will achieve these aims through a conducting a stepped-wedge trial conducted in 10 healthcare clinics in the state of Tennessee. The primary outcome is the proportion of women age 25-49 having risk assessment. Secondary outcomes include the numbers of 1) women identified as high-risk; 2) pursuing risk-adherent screening; and 3) diagnosed with breast cancer.
Investigators
Lucy Spalluto
Associate Professor of Radiology and Radiological Sciences
Vanderbilt University Medical Center
Eligibility Criteria
Inclusion Criteria
- •ages 25-49
Exclusion Criteria
- •personal history of breast cancer
Outcomes
Primary Outcomes
Number of Eligible Women Who Received Breast Cancer Risk Assessment
Time Frame: Baseline (2-months prior to intervention) to 9 months post-intervention
The number of women eligible for risk assessment who received documented breast cancer risk assessment.
Secondary Outcomes
- Number of Cancers Detected in Women Identified at High Risk.(Baseline (2-months prior to intervention) to 9 months post-intervention)
- Number of Women Who Received Risk Assessment Who Were Identified as High Risk for Breast Cancer.(Baseline (2-months prior to intervention) to 9 months post-intervention)
- Number of Women Identified as High Risk Women Who Received Breast Cancer Screening.(Baseline (2-months prior to intervention) to 9 months post-intervention)